The product information in this site is intended only for residents…

  The product information in this site is intended only for residents of the United States. The products
              discussed herein may have different product labeling in different countries.



About MACUGEN® (pegaptanib sodium injection)

If you have wet age-related macular degeneration (AMD), it is important to understand
your treatment so that you, along with your doctor, can do everything possible to
achieve the best outcome. In this web site, you'll find information on an innovative
treatment for wet AMD called MACUGEN (pegaptanib sodium injection). MACUGEN
can help you preserve your vision by slowing vision loss.

In December 2004, MACUGEN became the first anti-VEGF inhibitor to be approved by
the FDA for the treatment of wet AMD. While MACUGEN is effective at slowing vision
loss, it's still important to detect wet AMD as early as possible to help preserve vision.

For example, MACUGEN treatment given every 6 weeks for up to 2 years has been
shown to significantly reduce the risk of moderate vision loss in patients with all types of
wet AMD. Data suggests that patients who had early wet AMD and were treated with
MACUGEN had improved vision outcomes than those who started treatment later.
These kinds of results highlight the importance of beginning treatment before wet AMD
becomes advanced and routine activities become difficult.

Learn more about WET AMD

FREE NEWSLETTER:
The more you know the more you can do. Keep informed by signing-up to receive
additional information about wet AMD and MACUGEN.

IS MACUGEN RIGHT FOR YOU?
Watch this video and get the answers you need about Wet AMD and treatment with
MACUGEN.

Uninsured? Need help paying for medicine? Pfizer has programs that can help, no
matter your age or income. You may even qualify for free Pfizer medicines. Call 1-866-
706-2400. Click here for more info www.pfizerhelpfulanswers.com.

To listen to the full prescribing information regarding Macugen, please click on the link
entitled important safety information on the menu bar, located on the left of the screen.
MACUGEN is approved to treat wet age-related macular degeneration. It is available
by prescription only.

Not all people respond the same to MACUGEN, so individual results may vary. The
safety or efficacy of MACUGEN has not been proven beyond 2 years.

Important safety information
With MACUGEN, you may have some side effects, mostly in the eye and due to the
injection procedure. The most common side effects are burning sensation, eye pain,
redness, light sensitivity, vision loss, blurred vision, visual disturbances, high blood
pressure, and cataract. For a complete list of side effects, please ask your doctor or see
the prescribing information.

You should not receive MACUGEN if you have an infection in or around your eye or if
you are hypersensitive (allergic) to pegaptanib sodium or any of the other ingredients.

A serious eye infection can sometimes develop after an injection into the eye. Signs of a
serious infection may include eye pain, light sensitivity, and/or vision changes. Check
with a retinal physician immediately if you experience any of these symptoms, so you
can be treated early if an infection occurs.

Eye injections like those with MACUGEN can increase eye pressure. This is something
you would not notice; however, your retinal physician may do some extra tests after
your injection to make sure there are no complications.

In rare cases, allergic reactions have been known to occur. Tell your retinal physician
about any known allergies.

Please follow your retinal physician's recommendations for your therapy. If you have
any questions about MACUGEN, ask your retinal physician.

The health information contained herein is provided for educational purposes only and
is not intended to replace discussions with a health care provider. All decisions
regarding patient care must be made with a health care provider, considering the unique
characteristics of the patient.

Copyright 2006 (OSI) Eyetech Pharmaceuticals, Inc., and Pfizer Inc. All rights reserved.

The product information in this site is intended only for residents of the United States.
The products discussed herein may have different product labeling in different
countries.

Pfizer is a licensee of the TRUSTe Privacy Program.
MU277755